發(fā)布時(shí)間：2018-02-01 21:46

  本文關(guān)鍵詞： 大腸癌 肝癌 肝腎陰虛證 蛋白質(zhì)組學(xué) 差異表達(dá)蛋白 同位素相對(duì)標(biāo)記與絕對(duì)定量技術(shù)　出處：《中華中醫(yī)藥雜志》2017年06期 　論文類型：期刊論文

【摘要】：目的:篩選大腸癌和肝癌術(shù)后肝腎陰虛證的血漿差異表達(dá)蛋白,探索大腸癌和肝癌"異病同證"的物質(zhì)基礎(chǔ)。方法:納入具有典型肝腎陰虛證的大腸癌和肝癌患者各10例,對(duì)照組為無(wú)證可辨的大腸癌和肝癌患者各10例。采集患者血漿并提取蛋白,然后進(jìn)行蛋白變性、還原及酶解,最后進(jìn)行同位素相對(duì)標(biāo)記與絕對(duì)定量技術(shù)(i TRAQ)標(biāo)記和液相色譜串聯(lián)質(zhì)譜聯(lián)用技術(shù)鑒定,得到的峰圖采用Maxquant 1.3.0.5軟件進(jìn)行系統(tǒng)的蛋白差異表達(dá)分析。鑒定蛋白組間比值1.5或0.6被認(rèn)為存在表達(dá)差異。結(jié)果:大腸癌術(shù)后肝腎陰虛證組共篩選出9個(gè)典型的差異表達(dá)蛋白,肝癌術(shù)后肝腎陰虛證組也篩選出9個(gè)典型差異表達(dá)蛋白,兩組共同的差異蛋白有8個(gè):激肽原1(KNG1)、血紅蛋白α2(HBA2)、血紅蛋白β(HBB)、α1微球蛋白比庫(kù)蛋白前體(AMBP)、性激素結(jié)合球蛋白(SHBG)、羧肽酶N催化鏈(CPN1)、血漿蛋白酶C1抑制劑(SERPING1)、間α胰蛋白酶抑制劑重鏈H1(ITHIH1)。這些蛋白主要與補(bǔ)體和凝血級(jí)聯(lián)途徑有緊密聯(lián)系。結(jié)論:本研究證實(shí)i TRAQ結(jié)合液相色譜串聯(lián)質(zhì)譜聯(lián)用技術(shù)能夠快速、有效地進(jìn)行差異蛋白質(zhì)組學(xué)研究,發(fā)現(xiàn)KNG1,HBA2等蛋白可能是大腸癌和肝癌"異病同證"的物質(zhì)基礎(chǔ)之一。
[Abstract]:Objective: to screen plasma differentially expressed proteins for liver and kidney yin deficiency syndrome after operation of colorectal cancer and liver cancer. Methods: 10 cases of colorectal cancer and 10 cases of liver cancer with typical liver and kidney yin deficiency syndrome were included. The control group consisted of 10 patients with colorectal cancer and 10 patients with liver cancer. The patients' plasma was collected and protein was extracted. Then protein denaturation, reduction and enzymatic hydrolysis were performed. Isotope relative labeling, absolute quantitative technique and liquid chromatography-tandem mass spectrometry (LC-MS) were used for identification. Maxquant 1.3.0.5 software was used to analyze the differential expression of protein. The ratio of 1. 5 or 0. 6 was identified to be different. Nine typical differentially expressed proteins were screened out in patients with liver and kidney yin deficiency syndrome after colorectal cancer operation. Nine typical differentially expressed proteins were also screened out in liver and kidney yin deficiency syndrome group after liver cancer operation. There were 8 common differentially expressed proteins in the two groups: kallikinogen 1 (KNG1), hemoglobin 偽 2 (HBA2). Hemoglobin 尾 #en0#, 偽 1 microglobulin precursor AMBP, sex hormone binding globulin (SHBG), carboxypeptidase N catalytic chain (CPN 1). Plasma protease C1 inhibitor SERPING1). 偽 -trypsin inhibitor heavy chain H _ 1 _ 1 _ (ITH _ H _ 1). These proteins are closely related to complement and coagulation cascade pathway. Conclusion: I TRAQ combined with liquid chromatography-tandem mass spectrometry can be used quickly. Through effective differential proteomics study, it was found that KNG1, HBA2 and other proteins may be one of the material bases for the "syndromes of different diseases" between colorectal cancer and liver cancer.
【作者單位】： 上海中醫(yī)藥大學(xué)復(fù)雜系統(tǒng)研究中心;上海中醫(yī)藥大學(xué)附屬曙光醫(yī)院;上海中醫(yī)藥大學(xué)附屬第七人民醫(yī)院腫瘤科;
【基金】：國(guó)家自然科學(xué)基金項(xiàng)目(No.81330084,No.81303102,No.81573749) 浦東新區(qū)衛(wèi)生系統(tǒng)重點(diǎn)學(xué)科建設(shè)項(xiàng)目(No.PWZxq2014-12) 上海市局級(jí)課題項(xiàng)目(No.20134173)~~
【分類號(hào)】：R735
【正文快照】： 近些年,由于飲食方式和生活習(xí)慣的變化,大腸癌的發(fā)病率逐年上升,升幅越居榜首[1]。ⅡB期以上或具有高危因素的Ⅱ期大腸癌術(shù)后患者化療和(或)放療后仍有約50%患者于根治術(shù)后2年內(nèi)出現(xiàn)復(fù)發(fā)或轉(zhuǎn)移。中醫(yī)認(rèn)為,大腸癌患者臨床常見(jiàn)證型有濕熱蘊(yùn)結(jié)型、瘀毒內(nèi)阻型、脾虛氣滯型、肝腎陰

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 翁莉;杜鵑;何文婷;凌昌全;;原發(fā)性肝癌肝腎陰虛證患者外周血單個(gè)核細(xì)胞的特征性差異基因[J];中西醫(yī)結(jié)合學(xué)報(bào);2012年04期

相關(guān)會(huì)議論文 前1條

1 翁莉;杜鵑;何文婷;凌昌全;;原發(fā)性肝癌肝腎陰虛證患者外周血單個(gè)核細(xì)胞差異基因的研究[A];2012·中國(guó)醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合醫(yī)師大會(huì)第三次會(huì)議論文集[C];2012年

相關(guān)博士學(xué)位論文 前1條

1 翁莉;原發(fā)性肝癌肝腎陰虛證外周血單個(gè)核細(xì)胞差異基因的研究[D];第二軍醫(yī)大學(xué);2012年

，

本文編號(hào)：1482942